XCUR Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Exicure Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerXCUR

Market Cap20.6M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Exicure Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for AST-008 in Healthy Volunteer Study (Phase 1).

Pipeline

Asset	Indication	Modality	Stage	Public Note
AST-008	Healthy Volunteer Study	n/a	Phase 1	Public pipeline row
Cavrotolimod	n/a	n/a	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03086278	Phase 1	COMPLETED	16	2018-08-16
NCT03684785	Phase 1 \| Phase 2	TERMINATED	57	2022-03-30

Scientific Context

literature_publication | Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
asset_name | AST-008
asset_name | AST-008
asset_name | AST-008
asset_name | AST-008

Want the full XCUR research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.